Ciconte Giuseppe, Giacopelli Daniele, Pappone Carlo
Department of Arrhythmology, IRCCS Policlinico San Donato, University of Milan, San Donato Milanese (MI), Italy.
Biotronik Italia, Clinical Research, Vimodrone (MI), Italy.
J Atr Fibrillation. 2017 Aug 31;10(2):1590. doi: 10.4022/jafib.1590. eCollection 2017 Aug-Sep.
Continuous heart rhythm monitoring using implantable cardiac monitors (ICMs) for atrial fibrillation (AF) management is steadily increasing in current clinical practice, even in the absence of an established indication provided by international guidelines. The increasing use of such devices is mainly associated with recent technological improvements including miniaturization, easier implant procedures, and remote monitoring, all of which make this strategy continuously more appealing and promising. For these and other reasons, ICMs have been proven to be a safe and highly effective tool for detecting AF episodes. However, ICMs are not the best option for every patient, as limitations exist. Therefore, it is imperative to weigh the possible benefits against the potential limitations of using these devices when deciding individualized patient care.
在当前临床实践中,使用植入式心脏监测器(ICM)进行房颤(AF)管理的连续心律监测正在稳步增加,即使在缺乏国际指南规定的既定适应症的情况下也是如此。此类设备使用的增加主要与近期的技术改进有关,包括小型化、植入程序更简便以及远程监测,所有这些都使该策略越来越有吸引力且前景广阔。由于这些及其他原因,ICM已被证明是检测房颤发作的安全且高效的工具。然而,ICM并非适用于每个患者,因为存在局限性。因此,在决定个体化患者护理时,权衡使用这些设备可能带来的益处与潜在局限性至关重要。